Key facts
- This page summarizes Luke Evnin's Form 4 filing for Werewolf Therapeutics, Inc. (HOWL).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 29 Oct 2025, 19:22.
Luke Evnin - 27 Oct 2025 Form 4 Insider Report for Werewolf Therapeutics, Inc. (HOWL)
- Reporting relationship
- Director
- Issuer ticker
- HOWL
- Reported as of
- 27 Oct 2025
- Net transaction value
- -$286,497
- SEC form
- 4
- Accepted by SEC
- 29 Oct 2025, 19:22:38 UTC
- Prior SEC filing
- 13 Jun 2025
- Next SEC filing
- 03 Nov 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Luke Evnin
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Luke Evnin filed Form 4 for Werewolf Therapeutics, Inc. (HOWL) on 29 Oct 2025.
Change
- Previous filing in this sequence was filed on 13 Jun 2025.
- Current net transaction value: -$286,497.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001134657
Primary reporting owner
EVNIN LUKE
- Relationship
- Director
- Address
- C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON
- Signature
- /s/ Luke Evnin
- Signature date
- 29 Oct 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
HOWL
transaction
Common Stock
Sale
- Transaction value
- $80,262
- Shares
- -46,664
- Change %
- -1.1%
- Price
- $1.72
- Shares after
- 4,263,196
- Date
- 27 Oct 2025
- Ownership
- See Footnote
- Footnotes
- F1, F2, F3, F4
HOWL
transaction
Common Stock
Sale
- Transaction value
- $72,696
- Shares
- -44,327
- Change %
- -1%
- Price
- $1.64
- Shares after
- 4,218,869
- Date
- 28 Oct 2025
- Ownership
- See Footnote
- Footnotes
- F1, F5, F6, F7
HOWL
transaction
Common Stock
Sale
- Transaction value
- $133,539
- Shares
- -86,154
- Change %
- -2%
- Price
- $1.55
- Shares after
- 4,132,715
- Date
- 29 Oct 2025
- Ownership
- See Footnote
- Footnotes
- F1, F8, F9, F10
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 10 footnotes
Footnote F1
Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
Footnote F2
The shares were sold as follows: 4,992 by MPM Asset Management LLC ("AM LLC"), 31,538 by MPM BioVentures 2014, L.P. ("BV 2014"), 2,104 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 1,085 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 6,945 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.675 to $1.82 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F4
The shares are held as follows: 456,416 by AM LLC, 2,882,585 by BV 2014, 192,263 by BV 2014(B), 99,218 by AM BV2014 and 632,714 by MPM OIF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Footnote F5
The were sold as follows: 4,742 by AM LLC, 29,958 by BV 2014, 1,998 by BV 2014(B), 1,031 by AM BV2014 and 6,598 by MPM OIF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Footnote F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.605 to $1.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F7
The shares are held as follows: 451,674 by AM LLC, 2,852,627 by BV 2014, 190,265 by BV 2014(B), 98,187 by AM BV2014 and 626,116 by MPM OIF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Footnote F8
The were sold as follows: 9,216 by AM LLC, 58,227 by BV 2014, 3,884 by BV 2014(B), 2,004 by AM BV2014 and 12,823 by MPM OIF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Footnote F9
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.51 to $1.62 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F10
The shares are held as follows: 442,458 by AM LLC, 2,794,400 by BV 2014, 186,381 by BV 2014(B), 96,183 by AM BV2014 and 613,293 by MPM OIF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.